Literature DB >> 2982388

Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.

R A Boas, J W Villiger.   

Abstract

Receptor binding assays were undertaken in an attempt to elucidate the opioid binding characteristics of fentanyl and buprenorphine, and to investigate some of the differences between them. Buprenorphine showed slow receptor association (30 min), but with high affinity to multiple sites from which dissociation was very slow (T 1/2 = 166 min) and incomplete (50% binding after 1 h). This contrasted with the receptor binding of fentanyl, which achieved rapid equilibrium (within 10 min) and dissociated equally rapidly (T 1/2 = 6.8 min) and completely (100% by 1 h). Competitive displacement showed buprenorphine displacement of fentanyl binding was concentration- and time-dependent over ranges encountered in clinical use, but buprenorphine binding was displaced with only very high concentrations of other opioids. These findings offer pharmacodynamic explanations for the differences in fentanyl and buprenorphine analgesic response profiles and suggest how binding interactions might be applied to therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982388     DOI: 10.1093/bja/57.2.192

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  37 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction.

Authors:  Gang Yu; Shu-Hui Li; Meng-Xun Cui; Ling-Di Yan; Zheng Yong; Pei-Lan Zhou; Rui-Bin Su; Ze-Hui Gong
Journal:  CNS Neurosci Ther       Date:  2013-12-16       Impact factor: 5.243

Review 3.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

4.  Effects of Buprenorphine, Methylnaltrexone, and Their Combination on Gastrointestinal Transit in Healthy New Zealand White Rabbits.

Authors:  Manuel Martin-Flores; Bhupinder Singh; Courtney A Walsh; Elizabeth P Brooks; Lacic Taylor; Lisa M Mitchell
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

Review 5.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

6.  Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Authors:  Emily C Eastwood; Amy J Eshleman; Aaron Janowsky; Tamara J Phillips
Journal:  Mamm Genome       Date:  2017-11-10       Impact factor: 2.957

Review 7.  To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.

Authors:  T Anthony Anderson; Aurora N A Quaye; E Nalan Ward; Timothy E Wilens; Paul E Hilliard; Chad M Brummett
Journal:  Anesthesiology       Date:  2017-06       Impact factor: 7.892

8.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Newer methods of delivery of opiates for relief of pain.

Authors:  P J Slattery; R A Boas
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

10.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.